Incyte Tumbles On More Jakafi Trial Terminations

Incyte Corporation is discontinuing all ongoing trials for its Janus kinase inhibitor, Jakafi (ruxolitinib), in solid tumors following poor results in a Phase III study in metastatic pancreatic cancer and in a recently suspended Phase II colorectal cancer trial.

Incyte Corporation is discontinuing all ongoing trials for its Janus kinase inhibitor, Jakafi (ruxolitinib), in solid tumors following poor results in a Phase III study in metastatic pancreatic cancer and in a recently suspended Phase II colorectal cancer trial.

The decision to stop the Phase III JANUS 1 study was made after a planned interim analysis demonstrated that Jakafi...

Scrip Podcast

Keep up with the top pharma business news of the week. On the go.

Scrip brings you a weekly bulletin of top picks.

More from Anticancer

More from Therapeutic Category